Are GLP-1 Weight Loss Drugs Cost-Effective? Systematic Review of Economic Evidence
Systematic review of obesity drug economics finds GLP-1 agonists are cost-effective when long-term health benefits are considered, despite high upfront drug costs.
Quick Facts
What This Study Found
GLP-1 obesity drugs generally meet cost-effectiveness thresholds when long-term complication prevention and quality of life improvements are factored into the analysis.
Key Numbers
Four databases were searched. PRISMA guidelines were followed. Specific cost-effectiveness ratios were analyzed across included studies.
How They Did This
Systematic review of published economic evaluations of obesity prevention and treatment medications, with focus on cost-effectiveness analysis methodology and outcomes.
Why This Research Matters
Insurance coverage and healthcare budgets depend on cost-effectiveness evidence. Demonstrating that GLP-1 drugs save money long-term through prevented complications supports broader coverage and access.
The Bigger Picture
The cost-effectiveness debate will determine who gets access to GLP-1 drugs. This review provides the evidence base for policymakers, insurers, and healthcare systems deciding whether to fund these expensive but effective medications.
What This Study Doesn't Tell Us
Economic models depend on assumptions about long-term outcomes, drug pricing, and complication rates. Different healthcare systems have different cost-effectiveness thresholds. Rapidly changing drug prices affect conclusions.
Questions This Raises
- ?At what drug price do GLP-1 obesity drugs become cost-effective for all obese patients?
- ?Will biosimilar GLP-1 drugs dramatically improve cost-effectiveness?
- ?Should cost-effectiveness models include productivity gains from weight loss?
Trust & Context
- Key Stat:
- Cost-effective long-term GLP-1 obesity drugs meet cost-effectiveness thresholds when prevented cardiovascular events, diabetes, and other complications are factored in
- Evidence Grade:
- Strong evidence: systematic review of published economic evaluations with well-defined methodology assessment.
- Study Age:
- Published in 2025. Most comprehensive review of GLP-1 drug cost-effectiveness for obesity.
- Original Title:
- Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review.
- Published In:
- International journal of preventive medicine, 16, 56 (2025)
- Authors:
- Afshari, Somaye, Khosravi, Majid, Zamandi, Mahmood, Rezapour, Aziz, Hadian, Marziye, Souresrafil, Aghdas, Mazaheri, Elaheh, Gallehzan, Nasrin Abolhasanbeigi
- Database ID:
- RPEP-09775
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Are GLP-1 drugs worth the cost?
Economically, yes — when long-term benefits are considered. The ,000+/month drug cost is offset by preventing expensive complications: heart attacks, diabetes, kidney disease, joint replacements, and cancer. Cost-effectiveness improves in patients with more comorbidities.
Why won't my insurance cover GLP-1 drugs?
Many insurers focus on short-term drug costs rather than long-term savings. This review provides evidence that GLP-1 drugs are cost-effective long-term. Sharing this evidence with your insurer or appealing coverage decisions may help.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09775APA
Afshari, Somaye; Khosravi, Majid; Zamandi, Mahmood; Rezapour, Aziz; Hadian, Marziye; Souresrafil, Aghdas; Mazaheri, Elaheh; Gallehzan, Nasrin Abolhasanbeigi. (2025). Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review.. International journal of preventive medicine, 16, 56. https://doi.org/10.4103/ijpvm.ijpvm_368_24
MLA
Afshari, Somaye, et al. "Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review.." International journal of preventive medicine, 2025. https://doi.org/10.4103/ijpvm.ijpvm_368_24
RethinkPeptides
RethinkPeptides Research Database. "Economic Evaluation of Medications in Prevention and Treatme..." RPEP-09775. Retrieved from https://rethinkpeptides.com/research/afshari-2025-economic-evaluation-of-medications
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.